Lucy Godley to Azacitidine
This is a "connection" page, showing publications Lucy Godley has written about Azacitidine.
Connection Strength
1.185
-
The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007 Sep; 48(9):1676-95.
Score: 0.292
-
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
Score: 0.141
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.121
-
The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia. 2014 Sep; 28(9):1765-73.
Score: 0.116
-
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther. 2014 May; 13(5):1334-44.
Score: 0.115
-
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013 Sep; 3(9):1002-19.
Score: 0.110
-
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
Score: 0.109
-
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.
Score: 0.083
-
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
Score: 0.043
-
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508.
Score: 0.033
-
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer. 2010 Jun 14; 10:286.
Score: 0.022